Unique stem cell lines identifier	NIAi001-A
	NIAi001-B
	NIAi001-C
	NIAi001-D
	NIAi001-E
	NIAi001-F
	NIAi001-G
	NIAi001-H
	NIAi001-I
	NIAi001-K
	NIAi001-L
	NIAi001-M
	NIAi001-N
Alternative names of stem cell lines	LRRK2 I2020T PL2F4 (NIAi001-A)
	LRRK2 I2020T PL2D7 (NIAi001-B)
	LRRK2 G2019S PL2A9 (NIAi001-C)
	LRRK2 G2019S PL2H7 (NIAi001-D)
	LRRK2 Y1699C PL3H2 (NIAi001-E)
	LRRK2 Y1699C PL2H7 (NIAi001-F)
	LRRK2 R1441C PL2F5 (NIAi001-G)
	LRRK2 R1441C PL3C2 (NIAi001-H)
	LRRK2 N1437H PL3D7 (NIAi001-I)
	LRRK2 N1437H PL3F5 (NIAi001-J)
	LRRK2 K1906M PL2H7 (NIAi001-K)
	LRRK2 T1348N PL1B6 (NIAi001-L)
	LRRK2 KO PL1C4 (NIAi001-M)
	LRRK2 KO PL1C6 (NIAi001-N)
Institution	National Institutes of Health, National Institute on Aging
Contact information of distributor	Mark Cookson: cookson@mail.nih.gov
Type of cell lines	iPSC
Origin	Human
Cell Source	A18945 (Thermo Scientific, cat # A18945)
Clonality	Clonal
Method of reprogramming	A18945 cell line was derived from CD34 + cord blood using a three-plasmid, seven-factor (SOKMNLT; SOX2, OCT4 (POU5F1), KLF4, MYC, NANOG, LIN28, and SV40L T antigen) EBNA-based episomal system
Multiline rationale	Isogenic clones
Gene modification	Yes
Type of modification	Induced mutation
Associated disease	Parkinson’s disease
Gene/locus	LRRK2/PARK8
Method of modification	CRISPR/Cas9
Name of transgene or resistance	N/A
Inducible/constitutive system	N/A
Date archived/stock date	N/A
Cell line repository/bank	N/A
Ethical approval	Original line obtained from Thermo Scientific. Ethical license/patient consent: −45 CFR Part 46, IRB SOP RR 404.